Summary The c-erbB-2 product is thought to be a unique and useful target for antibody therapy of cancers overexpressing the c-erbB-2 gene. In vitro and in vivo anti-tumour effects of a humanised antibody against the extracellular domain of the c-erbB-2 gene product, rhu4D5, were examined. Rhu4D5 was less effective than its murine counterpart, mu4D5, for the direct antiproliferative activity against the c-erbB-2-overexpressing SK-BR-3 cell line. In vivo treatment of severe combined immunodeficient (SCID) mice carrying the c-erbB-2-overexpressing 4-1ST human gastric carcinoma xenograft with rhu4D5 revealed that the recombinant protein had potent anti-tumour activity. Furthermore, cytotoxicity of human peripheral blood mononuclear cells against 4-1ST was significantly augmented with rhu4D5, but not with mu4D5. These results indicate that rhu4D5 might perform better in patients than predicted from preclinical studies.
The c-erbB-2/HER-2 proto-oncogene encodes a receptor-type tyrosine kinase (Yarden and Ullrich, 1988) related to, but distinct from, the epidermal growth factor receptor (Coussens et al., 1985; Yamamoto et al., 1986) . The cell surface protein consists of extracellular, transmembrane and intracellular domains, the latter possessing kinase activity capable of autophosphorylation. Appreciable amplification and/or overexpression of this gene has been demonstrated in a variety of adenocarcinomas including breast, ovarian, lung and gastric cancers (King et al., 1985; Yokota et al., 1986 ; Van de Vijver et al., 1987; Slamon et al., 1989 ; Kern et al., 1990) . However, the expression of this gene in normal adult tissues is weak (De Potter et al., 1989; Press et al., 1990) . Therefore, the cerbB-2 product is thought to be a useful target for antibody therapy of cancers overexpressing the c-erbB-2 gene.
Several series of murine monoclonal antibodies (MAbs) directed against the extracellular domain of the c-erbB-2 gene product have already been reported to have in vitro and in vivo anti-tumour effects (Drebin et al., 1985; Hudziak et al., 1989; Hancock et al., 1991; Tagliabue et al., 1991; Stancovski et al., 1991; Harwerth et al., 1992; Kasprzyk et al., 1992) . However, human anti-mouse antibody response during therapy would be a major limitation in the clinical application of such murine MAbs (Schroff et al., 1985; Shawler et al., 1985) . Therefore, Carter and his colleagues constructed a 'humanised' antibody containing only the antigen-binding loops from a murine MAb against the extracellular domain of the c-erbB-2 gene product and human variable region framework residues plus IgG, constant domains (Carter et al., 1992) .
In this study, we investigated the in vitro and in vivo antitumour effects of the humanised antibody in comparison with its murine counterpart.
Materials and methods
Cell lines and xenotransplanted tumour lines Human tumour cell lines, SK-BR-3, BT474, MDA-MB-453, MCF7, ZR-75-1, (1983) . Briefly, the cells were cultured for 3 days with various concentrations of the anti-c-erbB-2 antibodies, mu4D5 and rhu4D5, in 96-well flatbottom microplates. MTT (Sigma) solution (final concentration, 0.5 mg ml-') was added to the wells and the plates were incubated at 37°C for 5 h. Then, acid-isopropanol was added to the wells. The plates of triplicate samples were read on a microelisa reader (SLT Labinstruments, Salzburg, Austria) using a wavelength of 570 nm to determine relative cell proliferation (per cent of control).
Antibody-dependent cell-mediated cytotoxicity (ADCC) Freshly isolated peripheral blood mononuclear cells (PBMC) from normal donors and spleen cells of Balb/cA-nu mice were serially diluted into 96-well round-bottom microplates with various dilutions of the antibodies and 2500 per well of target tumour cells. The cytotoxicity was determined by a 4 h 51Cr-release assay. Each assay was performed in triplicate. Per cent cytotoxicity was calculated as described previously (Tokuda et al., 1989) . Some results were expressed as lytic units per 106 cells, with one lytic unit being the number of effector cells required to cause 30% lysis of target cells. The exponential fit equation and per cent lysis with four effector/target cell ratios within each experiment were used to obtain the target cell survival curve and to calculate the lytic units.
In some experiments, solid tumours in nude mice were resected, finely dispersed using scissors, incubated in Hanks' balanced salt solution containing 0.05% pronase (Boehringer Mannheim, Germany), 0.02% collagenase type I (Sigma) and 0.02% DNAase I (Sigma) at 37°C for 30 min, and then passed through a nylon mesh to prepare single-cell suspensions to be used as a target for ADCC assays.
In vivo anti-tumour assay Effects on the tumours in the exponential growth phase were examined by a previously described method (Inaba et al., 1988) , in which nude mice were used instead of SCID mice.
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Results
The binding of rhu4D5 to the c-erbB-2 protein was first examined by flow cytometry and compared with that of mu4D5. Figure 1 summarises all the FACS data obtained from cell lines with rhu4D5 and mu4D5. No significant difference was observed between rhu4D5 and mu4D5 (Wilcoxon's signed rank test). IMR-32, which is a human glioma cell line with negative c-erbB-2 expression, was negative for both rhu4D5 and mu4D5.
The antiproliferative activity of the two antibodies was tested on a c-erbB-2-overexpressing human breast carcinoma cell line, SK-BR-3, by MTT assay. At concentrations ranging between 0.2 and 100 jug ml-' mu4D5 inhibited the growth of SK-BR-3 slightly more strongly than rhu4D5 (Figure 2) .
ADCC against SK-BR-3 of human PBMC with rhu4D5 and of murine splenocytes with mu4D5 was increased dependent on the dose of both antibodies reaching a plateau at more than 0.1 jIg ml-(data not shown). Thus, 1 Mg ml-1 of the antibodies was used in subsequent experiments.
Cytotoxicity of human PBMC against a variety of c-erbB-2-positive human tumour cell lines was significantly augmented in the presence of rhu4D5 (Figure 3 ), but the extent of killing was not correlated with the level of the c-erbB-2 expression (see Figure 1 ) (correlation coefficient=0.25, P=0.066 by Spearman's test). Cytotoxicity against c-erbB-2-negative IMR-32 was not changed in the presence or absence of the antibody.
The anti-tumour effects of rhu4D5 were examined in vivo in SCID mice transplanted with human gastric cancer 4-1ST and St-15. As reported previously (Ohnishi et al., 1995) , the 4-1ST tumour was found to express large amounts of the cerbB-2 protein at a similar level to SK-BR-3 by immunoblot- Humanised anti-c-erbB-2 antibody Y Tokuda et al 1364 ting and Northern analyses, whereas the St-15 tumour was found to express the c-erbB-2 protein at an undetectable level. SCID mice bearing 4-1ST or St-15 tumours were treated with a single intravenous administration of 36 mg kg-' of rhu4D5 or human IgG, when the tumour volume reached 100-300 mm3. Even 4 days after treatment, %T/C of 4-1ST was significantly reduced to 50%. However, %T/C of St-15 was more than 100%. The difference in %T/C between 4-1ST and St-15 was significant by the Mann -Whitney U-test (Figure 4) . On the other hand, mu4D5 was more potent in inhibiting the growth of the 4-1ST xenograft ( Figure 5 ).
To examine a role of ADCC in SCID mice treated with rhu4D5 and mu4D5, 4-1ST tumour cells were cultured for a short period and used as targets for ADCC assays. As shown in Figure 6 , cytotoxicity of murine splenocytes was not augmented with mu4D5, whereas cytotoxicity of human PBMC was strongly augmented by rhu4D5.
Discussion
The c-erbB-2 product is thought to be a unique and useful target for antibody therapy of cancers overexpressing the cerbB-2 gene. Several series of murine MAbs directed against the extracellular domain of the c-erbB-2 gene product have been developed and examined to reveal their anti-tumour effects, mainly in vitro. However, human anti-mouse antibody response during therapy would be a major limitation on the clinical application of such murine MAbs. Therefore, a BT474 MCF7 MUA-MB-453 Li-75 1  MKN7  MKN45  KATOIII  IMR-32 humanised antibody against the c-erbB-2 gene product is expected to be useful in clinical trials if its anti-tumour effects in vitro and in vivo are similar to those of its murine counterpart. As Carter and his colleagues designed rhu4D5 to bind its antigen 3-fold more tightly than mu4D5 by molecular modelling (Carter et al., 1992) , our flow cytometry analyses revealed that the binding of rhu4D5 to the surface molecule of the c-erbB-2 product was comparable with that of mu4D5. In vitro anti-proliferative activity of rhu4D5 against SK-BR-3 was also comparable with that of mu4D5 in the MTT assay as mentioned by Carter. Rhu4D5 was less potent in inhibiting the growth of 4-1ST xenografts in SCID mice. However, ADCC assays with rhu4D5 showed cytotoxicity against a variety of human tumour cell lines overexpressing the c-erbB-2 product. The extent of killing was not correlated with the level of the c-erbB-2 expression. This was however not surprising since susceptibility of the tumour cells to other cytotoxic functions such as spontaneous cytotoxicity was variable. Cytotoxicity of human PBMC against 4-1ST was significantly augmented with rhu4D5, but not with mu4D5. Thus, rhu4D5 may be predicted to have greater anti-tumour potency in clinical trials than mu4D5.
There have been no published reports on in vivo antitumour effects of humanised antibodies against the c-erbB-2 products, although rhu4D5 is currently undergoing evaluation in the treatment of patients with breast cancer (Baselga et al., 1995) . Our preclinical study of rhu4D5 using SCID % 1365 mice clearly demonstrated in vivo anti-tumour effects even without human effector cells. although rhu4D5 was less effective than mu4D5. Since ADCC activity of munrne splenocytes With rhu4D5 against 4-1ST was similar to that with mu4D5. the difference might be partlv owing to the difference in the anti-proliferative actiVity. It was also likely that in SCID mice. the biodistribution of a murine antibody was altered less than that of a humanised antibody. In fact. the elimiination half-life of a human monoclonal antibody was much shorter than that of a murine monoclonal antibody when administered to mice (Larson et al.. 1983 : McCabe et al.. 1988 . Because the cvtotoxicitv of human PBMCs with
